Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections

Dalbavancin is a lipoglycopeptide antibiotic recently approved by the United States Food and Drug Administration (FDA) for acute bacterial skin and skin structure infections (ABSSSIs). It is active against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and min...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Jordan R., Roberts, Karrine D., Rybak, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575294/
https://www.ncbi.nlm.nih.gov/pubmed/26341488
http://dx.doi.org/10.1007/s40121-015-0077-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575294/
https://www.ncbi.nlm.nih.gov/pubmed/26341488
http://dx.doi.org/10.1007/s40121-015-0077-7

Ejemplares similares